SEC Form 4 · accession 0002141314-26-000004
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Gregory Cohen
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 9:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000879407
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2026 | A | 11,882 | $0.00 | A | 11,882 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.